Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
MLEC vs ECX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
MLEC Captures Overall Composite Edge (40.8 SELL vs 52.4 HOLD), While ECX Leads 4–1 on Growth & Valuation Pillars
MLEC Overall Winner
6-Pillar Tally: MLEC 1 – 4 ECX (1 Tie)
Matrix Metrics: MLEC 5 – 4 ECX
As of Nov 19, 2026, Moolec Science SA (MLEC) captures the overall head-to-head institutional edge over ECARX Holdings Inc. Class A (ECX) on higher Unified Composite conviction (40.8/100 SELL vs. 52.4/100 HOLD) after splitting the core matrix 5–4 (led by Profitability & Quality), while ECX wins 4–1 across the 6-pillar growth and valuation breakdown. MLEC trades at $0.85 (N/M Forward P/E, 0.0% operating margin) versus ECX at $0.69 (12.1x Forward P/E, -4.6% operating margin).
- Composite vs. Pillar Nuance: While ECX currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. MLEC 40.8/100 SELL), MLEC captures the overall institutional head-to-head verdict (5–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4.6% operating margin) and revenue trajectory (+948.3% vs. +9.5% YoY).
- Technical & Structure Timing Caution: MLEC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.8); meanwhile ECX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MLEC vs ECX
MLEC
Head-to-Head Winner
Moolec Science SA Ordinary Shares
$0.85
-39.29% 1D
Market Cap
$1.0M
TTM Revenue
$7.8M
Forward P/E
N/M
Beta / 30D Vol
0.05β · 208% Vol
Unified Composite Score
40.8
SELL
Tech 25.0
Fund 45.0
Flow 50.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
ECX
ECARX Holdings Inc. Class A Ordinary shares
$0.69
-9.78% 1D
Market Cap
$300.6M
TTM Revenue
$902M
Forward P/E
12.1x
Beta / 30D Vol
0.44β · 122% Vol
Unified Composite Score
52.4
HOLD
Tech 50.0
Fund 53.0
Flow 50.0
Mom 68.9
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (MLEC 1 – 4 ECX)
1. Valuation Multiples
ECX
Forward P/E
N/M
12.1x
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
0.1x
0.8x
2. Growth & Scale
ECX
Revenue Growth (YoY)
+948.3%
+9.5%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$7.8M
$902M
Market Cap
$1.0M
$300.6M
3. Profitability & Quality
MLEC
Gross Margin
-8.2%
15.3%
Operating Margin
0.0%
-4.6%
Net Profit Margin
0.0%
-7.4%
Return on Equity (ROE)
-174.7%
-2237.6%
4. Balance Sheet & Cash Flow
ECX
Cash Generation (TTM)
-$8.1M EBITDA
-$22M EBITDA
Cash Flow Margin
-103.1% EBITDA Mgn
-2.4% EBITDA Mgn
Net Cash / Leverage
$0.70 Book/Sh · -174.7% ROE
$466M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
ECX
OpEx & R&D Intensity
N/A
19.9% of Rev ($180M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Auto Parts Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MLEC (5) vs ECX (4)| Institutional Metric | MLEC | ECX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.0M | $300.6M | ECX | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | 12.1x | ECX | |
| Revenue Growth (YoY) | +948.3% | +9.5% | MLEC | |
| Operating Margin (TTM) | 0.0% | -4.6% | MLEC | |
| Net Profit Margin | 0.0% | -7.4% | MLEC | |
| Return on Equity (ROE) | -174.7% | -2237.6% | MLEC | |
| 52-Week Range Position | 3% ($0–$23) | 1% ($1–$2) | MLEC | |
| Beta / 30D Volatility | 0.05β · 208% Vol | 0.44β · 122% Vol | ECX | |
| Unified Institutional Score | 40.8 / 100 (SELL) | 52.4 / 100 (HOLD) | ECX | |
| Trailing 12M Revenue (USD) | $7.8M | $902M | Scale | |
| Gross Profit Margin (TTM) | -8.2% | 15.3% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.1x EV/Rev | N/M PEG · 0.8x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$8.1M EBITDA ($0.70 Book/Sh · -174.7% ROE) | -$22M EBITDA ($466M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ECX +99.77 pp
3M Horizon
ECX +80.46 pp
6M Horizon
ECX +83.62 pp
1Y Horizon
MLEC +94.87 pp
Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)
| Period | MLEC Revenue | ECX Revenue | MLEC Op. Margin | ECX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| Q4 '24 | $10M | N/A | -77.9% | N/A | MLEC |
| Q1 '25 | N/A | $670M | N/A | -14.7% | ECX |
| Q2 '25 | N/A | $620M | N/A | -24.0% | ECX |
| Q3 '25 | N/A | $880M | N/A | 1.5% | ECX |
| Q4 '25 | N/A | $1.22B | N/A | 3.9% | ECX |
| Q1 '26 | N/A | $530M | N/A | -9.9% | ECX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MLEC
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact MLEC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ECX
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ECX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MLEC Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ECX Moat Profile
Cyclical / Execution-Driven Positioning
Auto Parts Operator
OpEx & R&D Reinvestment
19.9% of Rev ($180M)
90D Engineering Disclosures
0 Published
Investor FAQ MLEC vs ECX Key Questions & Quantitative Answers
As of Nov 19, 2026, Moolec Science SA (MLEC) captures the overall head-to-head institutional edge over ECARX Holdings Inc. Class A (ECX) on higher Unified Composite conviction (40.8/100 SELL vs. 52.4/100 HOLD) after splitting the core matrix 5–4 (led by Profitability & Quality), while ECX wins 4–1 across the 6-pillar growth and valuation breakdown. MLEC trades at $0.85 (N/M Forward P/E, 0.0% operating margin) versus ECX at $0.69 (12.1x Forward P/E, -4.6% operating margin). Composite vs. Pillar Nuance: While ECX currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. MLEC 40.8/100 SELL), MLEC captures the overall institutional head-to-head verdict (5–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4.6% operating margin) and revenue trajectory (+948.3% vs. +9.5% YoY). Technical & Structure Timing Caution: MLEC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.8); meanwhile ECX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ECX leads the Growth & Scale pillar: MLEC posts +948.3% YoY revenue growth and +0.0% YoY earnings growth on $7.8M TTM revenue (-8.2% gross margin, 0.0% operating margin), compared with ECX at +9.5% YoY revenue growth and +0.0% YoY earnings growth on $902M TTM revenue (15.3% gross margin, -4.6% operating margin). Across the 6-period historical trajectory (Q4 '24 to Q1 '26), MLEC cumulative revenue shifted N/A while ECX shifted -20.9%. In operating R&D and SG&A reinvestment, MLEC deploys N/A (0 90-day corporate R&D disclosures) versus 19.9% of Rev ($180M) (0 disclosures) for ECX.
ECX screens cheaper on headline valuation multiples. MLEC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-103.1% EBITDA margin), whereas ECX trades at 12.1x Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-2.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLEC (-174.7% ROE) versus ECX (-2237.6% ROE) capital efficiency.
In options market volatility and institutional positioning, MLEC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.05β · 208% Vol realized risk). By comparison, ECX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 122% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ECX vs MLEC · Reverse Pair
MLEC vs CMND
· Sector Peer
ECX vs SFWL
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal